Palvella Therapeutics (PVLA) Invested Capital (2013 - 2026)

Palvella Therapeutics (PVLA) has 14 years of Invested Capital data on file, last reported at $232.3 million in Q1 2026.

• Invested Capital for Q1 2026 came in at $232.3 million, up 303.64% year-over-year; the trailing twelve-month figure through Mar 2026 was $232.3 million (up 303.64% YoY), and the FY2025 annual result was $30.2 million, down 53.27% from the prior year.
• Invested Capital climbed to $232.3 million in Q1 2026 per PVLA's latest filing, from $30.2 million in the prior quarter.
• Over five years, Invested Capital peaked at $232.3 million in Q1 2026 and troughed at -$93.8 million in Q4 2022.
• A 5-year average of $15.4 million and a median of $35.5 million in 2023 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2024 and 2026: Invested Capital plunged 597.3% in 2024, then jumped 303.64% in 2026.
• A 5-year view of Invested Capital shows it stood at -$93.8 million in 2022, then grew by 20.57% to -$74.5 million in 2023, then soared by 186.71% to $64.6 million in 2024, then sank by 53.27% to $30.2 million in 2025, then jumped by 669.78% to $232.3 million in 2026.
• Business Quant data shows PVLA's Invested Capital at $232.3 million in Q1 2026, $30.2 million in Q4 2025, and $40.9 million in Q3 2025.